The case for prevention – primary hiv prevention in the era of universal test and treat: a mathematical modeling study

HIGHLIGHTS

• who: Katharine Kripke from the Avenir Health, Carroll Ave, Suite, Takoma Park, MD, USA have published the article: The case for prevention - Primary HIV prevention in the era of universal test and treat: A mathematical modeling study, in the Journal: (JOURNAL)
• what: Unlike HIV vaccines tested to date, for the purpose of this analysis, the HIV vaccine was optimistically assumed to have 80% efficacy (reduction in acquisition) and a 30-year duration of protection. This analysis demonstrates that for one-time interventions, the cost per HIV infection averted decreases (cost-effectiveness increases) as the time . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.